SAB Member Prof. Gerding interviewed by Equity Development

Professor Dale Gerding, a world leader in C. difficile infections and a member of the Destiny Pharma Scientific Advisory Board recently spoke to Equity Development about the significant problem of CDI and how Destiny Pharma’s novel NTCD-M3 clinical programme can provide a breakthrough in patients’ treatment. The interview can be viewed here